Hematopoietic stem cell transplantation for multiple sclerosis: A retrospective multicenter study

A. S. Fassas, J. R. Passweg, A. Anagnostopoulos, A. Kazis, T. Kozak, E. Havrdova, E. Carreras, F. Graus, A. Kashyap, H. Openshaw, M. Schipperus, E. Deconinck, G. Mancardi, A. Marmont, J. Hansz, M. Rabusin, F. J. Zuazu Nagore, J. Besalduch, T. Dentamaro, L. FouillardB. Hertenstein, G. La Nasa, M. Musso, F. Papineschi, J. M. Rowe, R. Saccardi, A. Steck, L. Kappos, A. Gratwohl, A. Tyndall

Research output: Contribution to journalArticle

216 Citations (Scopus)

Abstract

Rationale: Phase I/II studies of autologous hematopoietic stem cell transplantation (HSCT) for multiple sclerosis (MS) were initiated, based on results of experimental transplantation in animal models of multiple sclerosis and clinical observations in patients treated concomitantly for malignant disease. Patients: Eighty-five patients with progressive MS JON 800 were treated with autologous HSCT in 20 centers and reported to the autoimmune disease working party of the European Group for Blood and Marrow Transplantation (EBMT). 52 (61%) were female, median age was 39 [20-58] years. The median interval from diagnosis to transplant was 7 [1-26] years. Patients suffered from severe disease with a median EDSS score of 6.5 [4.5-8.5]. Active disease prior to transplant was documented in 79 of 82 evaluable cases. Results: The stem cell source was bone marrow in 6 and peripheral blood in 79, and stem cells were mobilized into peripheral blood using either cyclophosphamide combined with growth factors or growth factors alone. Three patients experienced transient neurological complications during the mobilization phase. The high dose regimen included combination chemotherapy, with or without anti-lymphocyte antibodies or, with or without, total body irradiation. The stem cell transplants were purged of lymphocytes in 52 patients. Median follow-up was 16 [3-59] months. There were 7 deaths, 5 due to toxicity and infectious complications, 2 with neurological deterioration. The risk of death of any cause at 3 years was 10 (±7)% (95% confidence interval). Neurological deterioration during transplant was observed in 22 patients; this was transient in most but was associated with MS progression in 6 patients. Neurological improvement by ≥ 1 point in the EDSS score was seen in 18 (21%) patients. Confirmed progression-free survival was 74 (±12)% at 3 years being 66 (±23)% in patients with primary progressive MS but higher in patients with secondary progressive or relapsing-remitting MS, 78 (±13)%; p = 0.59. The probability of confirmed disease progression was 20 (±11)%. MRI data were available in 78 patients before transplant showing disease activity (gadolinium enhancing, new or enlarging lesions) in 33%. Posttransplant MRI showed activity at any time in 5/61 (8%) evaluable cases. Conclusion: Autologous HSCT suggest positive early results in the management of progressive MS and is feasible. These multicentre data suggest an association with significant mortality risks especially in some patient groups and are being utilised in the planning of future trials to reduce transplant related mortality.

Original languageEnglish
Pages (from-to)1088-1097
Number of pages10
JournalJournal of Neurology
Volume249
Issue number8
DOIs
Publication statusPublished - 2002

Fingerprint

Hematopoietic Stem Cell Transplantation
Multicenter Studies
Multiple Sclerosis
Retrospective Studies
Transplants
Stem Cells
Intercellular Signaling Peptides and Proteins
Lymphocytes
Chronic Progressive Multiple Sclerosis
Relapsing-Remitting Multiple Sclerosis
Mortality
Whole-Body Irradiation
Gadolinium
Combination Drug Therapy
Cyclophosphamide
Autoimmune Diseases
Disease-Free Survival
Disease Progression
Cause of Death
Anti-Idiotypic Antibodies

Keywords

  • Hematopoietic stem cell transplantation
  • Multiple sclerosis

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology

Cite this

Fassas, A. S., Passweg, J. R., Anagnostopoulos, A., Kazis, A., Kozak, T., Havrdova, E., ... Tyndall, A. (2002). Hematopoietic stem cell transplantation for multiple sclerosis: A retrospective multicenter study. Journal of Neurology, 249(8), 1088-1097. https://doi.org/10.1007/s00415-002-0800-7

Hematopoietic stem cell transplantation for multiple sclerosis : A retrospective multicenter study. / Fassas, A. S.; Passweg, J. R.; Anagnostopoulos, A.; Kazis, A.; Kozak, T.; Havrdova, E.; Carreras, E.; Graus, F.; Kashyap, A.; Openshaw, H.; Schipperus, M.; Deconinck, E.; Mancardi, G.; Marmont, A.; Hansz, J.; Rabusin, M.; Zuazu Nagore, F. J.; Besalduch, J.; Dentamaro, T.; Fouillard, L.; Hertenstein, B.; La Nasa, G.; Musso, M.; Papineschi, F.; Rowe, J. M.; Saccardi, R.; Steck, A.; Kappos, L.; Gratwohl, A.; Tyndall, A.

In: Journal of Neurology, Vol. 249, No. 8, 2002, p. 1088-1097.

Research output: Contribution to journalArticle

Fassas, AS, Passweg, JR, Anagnostopoulos, A, Kazis, A, Kozak, T, Havrdova, E, Carreras, E, Graus, F, Kashyap, A, Openshaw, H, Schipperus, M, Deconinck, E, Mancardi, G, Marmont, A, Hansz, J, Rabusin, M, Zuazu Nagore, FJ, Besalduch, J, Dentamaro, T, Fouillard, L, Hertenstein, B, La Nasa, G, Musso, M, Papineschi, F, Rowe, JM, Saccardi, R, Steck, A, Kappos, L, Gratwohl, A & Tyndall, A 2002, 'Hematopoietic stem cell transplantation for multiple sclerosis: A retrospective multicenter study', Journal of Neurology, vol. 249, no. 8, pp. 1088-1097. https://doi.org/10.1007/s00415-002-0800-7
Fassas, A. S. ; Passweg, J. R. ; Anagnostopoulos, A. ; Kazis, A. ; Kozak, T. ; Havrdova, E. ; Carreras, E. ; Graus, F. ; Kashyap, A. ; Openshaw, H. ; Schipperus, M. ; Deconinck, E. ; Mancardi, G. ; Marmont, A. ; Hansz, J. ; Rabusin, M. ; Zuazu Nagore, F. J. ; Besalduch, J. ; Dentamaro, T. ; Fouillard, L. ; Hertenstein, B. ; La Nasa, G. ; Musso, M. ; Papineschi, F. ; Rowe, J. M. ; Saccardi, R. ; Steck, A. ; Kappos, L. ; Gratwohl, A. ; Tyndall, A. / Hematopoietic stem cell transplantation for multiple sclerosis : A retrospective multicenter study. In: Journal of Neurology. 2002 ; Vol. 249, No. 8. pp. 1088-1097.
@article{957935dabf2441099e38baff8daf861f,
title = "Hematopoietic stem cell transplantation for multiple sclerosis: A retrospective multicenter study",
abstract = "Rationale: Phase I/II studies of autologous hematopoietic stem cell transplantation (HSCT) for multiple sclerosis (MS) were initiated, based on results of experimental transplantation in animal models of multiple sclerosis and clinical observations in patients treated concomitantly for malignant disease. Patients: Eighty-five patients with progressive MS JON 800 were treated with autologous HSCT in 20 centers and reported to the autoimmune disease working party of the European Group for Blood and Marrow Transplantation (EBMT). 52 (61{\%}) were female, median age was 39 [20-58] years. The median interval from diagnosis to transplant was 7 [1-26] years. Patients suffered from severe disease with a median EDSS score of 6.5 [4.5-8.5]. Active disease prior to transplant was documented in 79 of 82 evaluable cases. Results: The stem cell source was bone marrow in 6 and peripheral blood in 79, and stem cells were mobilized into peripheral blood using either cyclophosphamide combined with growth factors or growth factors alone. Three patients experienced transient neurological complications during the mobilization phase. The high dose regimen included combination chemotherapy, with or without anti-lymphocyte antibodies or, with or without, total body irradiation. The stem cell transplants were purged of lymphocytes in 52 patients. Median follow-up was 16 [3-59] months. There were 7 deaths, 5 due to toxicity and infectious complications, 2 with neurological deterioration. The risk of death of any cause at 3 years was 10 (±7){\%} (95{\%} confidence interval). Neurological deterioration during transplant was observed in 22 patients; this was transient in most but was associated with MS progression in 6 patients. Neurological improvement by ≥ 1 point in the EDSS score was seen in 18 (21{\%}) patients. Confirmed progression-free survival was 74 (±12){\%} at 3 years being 66 (±23){\%} in patients with primary progressive MS but higher in patients with secondary progressive or relapsing-remitting MS, 78 (±13){\%}; p = 0.59. The probability of confirmed disease progression was 20 (±11){\%}. MRI data were available in 78 patients before transplant showing disease activity (gadolinium enhancing, new or enlarging lesions) in 33{\%}. Posttransplant MRI showed activity at any time in 5/61 (8{\%}) evaluable cases. Conclusion: Autologous HSCT suggest positive early results in the management of progressive MS and is feasible. These multicentre data suggest an association with significant mortality risks especially in some patient groups and are being utilised in the planning of future trials to reduce transplant related mortality.",
keywords = "Hematopoietic stem cell transplantation, Multiple sclerosis",
author = "Fassas, {A. S.} and Passweg, {J. R.} and A. Anagnostopoulos and A. Kazis and T. Kozak and E. Havrdova and E. Carreras and F. Graus and A. Kashyap and H. Openshaw and M. Schipperus and E. Deconinck and G. Mancardi and A. Marmont and J. Hansz and M. Rabusin and {Zuazu Nagore}, {F. J.} and J. Besalduch and T. Dentamaro and L. Fouillard and B. Hertenstein and {La Nasa}, G. and M. Musso and F. Papineschi and Rowe, {J. M.} and R. Saccardi and A. Steck and L. Kappos and A. Gratwohl and A. Tyndall",
year = "2002",
doi = "10.1007/s00415-002-0800-7",
language = "English",
volume = "249",
pages = "1088--1097",
journal = "Journal of Neurology",
issn = "0340-5354",
publisher = "Dr. Dietrich Steinkopff Verlag GmbH and Co. KG",
number = "8",

}

TY - JOUR

T1 - Hematopoietic stem cell transplantation for multiple sclerosis

T2 - A retrospective multicenter study

AU - Fassas, A. S.

AU - Passweg, J. R.

AU - Anagnostopoulos, A.

AU - Kazis, A.

AU - Kozak, T.

AU - Havrdova, E.

AU - Carreras, E.

AU - Graus, F.

AU - Kashyap, A.

AU - Openshaw, H.

AU - Schipperus, M.

AU - Deconinck, E.

AU - Mancardi, G.

AU - Marmont, A.

AU - Hansz, J.

AU - Rabusin, M.

AU - Zuazu Nagore, F. J.

AU - Besalduch, J.

AU - Dentamaro, T.

AU - Fouillard, L.

AU - Hertenstein, B.

AU - La Nasa, G.

AU - Musso, M.

AU - Papineschi, F.

AU - Rowe, J. M.

AU - Saccardi, R.

AU - Steck, A.

AU - Kappos, L.

AU - Gratwohl, A.

AU - Tyndall, A.

PY - 2002

Y1 - 2002

N2 - Rationale: Phase I/II studies of autologous hematopoietic stem cell transplantation (HSCT) for multiple sclerosis (MS) were initiated, based on results of experimental transplantation in animal models of multiple sclerosis and clinical observations in patients treated concomitantly for malignant disease. Patients: Eighty-five patients with progressive MS JON 800 were treated with autologous HSCT in 20 centers and reported to the autoimmune disease working party of the European Group for Blood and Marrow Transplantation (EBMT). 52 (61%) were female, median age was 39 [20-58] years. The median interval from diagnosis to transplant was 7 [1-26] years. Patients suffered from severe disease with a median EDSS score of 6.5 [4.5-8.5]. Active disease prior to transplant was documented in 79 of 82 evaluable cases. Results: The stem cell source was bone marrow in 6 and peripheral blood in 79, and stem cells were mobilized into peripheral blood using either cyclophosphamide combined with growth factors or growth factors alone. Three patients experienced transient neurological complications during the mobilization phase. The high dose regimen included combination chemotherapy, with or without anti-lymphocyte antibodies or, with or without, total body irradiation. The stem cell transplants were purged of lymphocytes in 52 patients. Median follow-up was 16 [3-59] months. There were 7 deaths, 5 due to toxicity and infectious complications, 2 with neurological deterioration. The risk of death of any cause at 3 years was 10 (±7)% (95% confidence interval). Neurological deterioration during transplant was observed in 22 patients; this was transient in most but was associated with MS progression in 6 patients. Neurological improvement by ≥ 1 point in the EDSS score was seen in 18 (21%) patients. Confirmed progression-free survival was 74 (±12)% at 3 years being 66 (±23)% in patients with primary progressive MS but higher in patients with secondary progressive or relapsing-remitting MS, 78 (±13)%; p = 0.59. The probability of confirmed disease progression was 20 (±11)%. MRI data were available in 78 patients before transplant showing disease activity (gadolinium enhancing, new or enlarging lesions) in 33%. Posttransplant MRI showed activity at any time in 5/61 (8%) evaluable cases. Conclusion: Autologous HSCT suggest positive early results in the management of progressive MS and is feasible. These multicentre data suggest an association with significant mortality risks especially in some patient groups and are being utilised in the planning of future trials to reduce transplant related mortality.

AB - Rationale: Phase I/II studies of autologous hematopoietic stem cell transplantation (HSCT) for multiple sclerosis (MS) were initiated, based on results of experimental transplantation in animal models of multiple sclerosis and clinical observations in patients treated concomitantly for malignant disease. Patients: Eighty-five patients with progressive MS JON 800 were treated with autologous HSCT in 20 centers and reported to the autoimmune disease working party of the European Group for Blood and Marrow Transplantation (EBMT). 52 (61%) were female, median age was 39 [20-58] years. The median interval from diagnosis to transplant was 7 [1-26] years. Patients suffered from severe disease with a median EDSS score of 6.5 [4.5-8.5]. Active disease prior to transplant was documented in 79 of 82 evaluable cases. Results: The stem cell source was bone marrow in 6 and peripheral blood in 79, and stem cells were mobilized into peripheral blood using either cyclophosphamide combined with growth factors or growth factors alone. Three patients experienced transient neurological complications during the mobilization phase. The high dose regimen included combination chemotherapy, with or without anti-lymphocyte antibodies or, with or without, total body irradiation. The stem cell transplants were purged of lymphocytes in 52 patients. Median follow-up was 16 [3-59] months. There were 7 deaths, 5 due to toxicity and infectious complications, 2 with neurological deterioration. The risk of death of any cause at 3 years was 10 (±7)% (95% confidence interval). Neurological deterioration during transplant was observed in 22 patients; this was transient in most but was associated with MS progression in 6 patients. Neurological improvement by ≥ 1 point in the EDSS score was seen in 18 (21%) patients. Confirmed progression-free survival was 74 (±12)% at 3 years being 66 (±23)% in patients with primary progressive MS but higher in patients with secondary progressive or relapsing-remitting MS, 78 (±13)%; p = 0.59. The probability of confirmed disease progression was 20 (±11)%. MRI data were available in 78 patients before transplant showing disease activity (gadolinium enhancing, new or enlarging lesions) in 33%. Posttransplant MRI showed activity at any time in 5/61 (8%) evaluable cases. Conclusion: Autologous HSCT suggest positive early results in the management of progressive MS and is feasible. These multicentre data suggest an association with significant mortality risks especially in some patient groups and are being utilised in the planning of future trials to reduce transplant related mortality.

KW - Hematopoietic stem cell transplantation

KW - Multiple sclerosis

UR - http://www.scopus.com/inward/record.url?scp=18544374335&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=18544374335&partnerID=8YFLogxK

U2 - 10.1007/s00415-002-0800-7

DO - 10.1007/s00415-002-0800-7

M3 - Article

C2 - 12195460

AN - SCOPUS:18544374335

VL - 249

SP - 1088

EP - 1097

JO - Journal of Neurology

JF - Journal of Neurology

SN - 0340-5354

IS - 8

ER -